UBS: Implications of Western Medtech Company Results for Japan's Medical Device Sector

Overview

This is a UBS industry research and earnings review on the Japanese medtech sector, with the core objective of extracting business implications for Japanese companies from the first-quarter results of Western medtech firms. The report focuses on business trends at Intuitive Surgical, Boston Scientific, and Roche, and maps them to related businesses at Japanese medical device companies such as Olympus, Terumo, and Asahi Intecc.

Core views

The report believes global medtech demand is differentiated but still has bright spots: surgical robot installations and procedure volumes continue to show strong growth, demand for cardiovascular intervention and vascular therapies is relatively steady, and diagnostics is performing better outside China; however, factors such as China's volume-based procurement and reimbursement cuts, hospital operating pressure, supply shortages, foreign exchange, and raw material costs may still weigh on the short-term performance of Japanese medical device companies.

Analysis framework

The report uses a peer earnings mapping approach: it first observes revenue growth by business segment, management commentary, and regional trends at overseas industry leaders, then infers the possible performance of Japanese listed medical device companies in similar product lines or end-demand areas. Key variables include YoY growth, regional demand, product mix differences, supply constraints, and changes in policy and reimbursement.

Methodology notes

• Industry peer mappingImplications from overseas leaders' earnings

  Infer demand trends for Japanese medtech companies through the results of Western medtech companies

  The report uses the segment-level performance of Intuitive Surgical, Boston Scientific, and Roche as external references to assess revenue momentum and risks for Japanese medical device companies in surgical robotics, endoscopy, urology, cardiovascular intervention, and diagnostics.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Olympus Corporation

  Japanese medtech company; its endoscopy and urology businesses are mapped from the performance of overseas peers

  Strengths

  There are product opportunities in endoscopy including AXIOS, a global distribution agreement for biliary stents, and products such as iTIND and RenaFlex.

  Weaknesses

  Endoscopy faces temporary supply shortages, and the urology business is affected by remediation measures and China's volume-based procurement.

  Comparison

  Boston Scientific's endoscopy revenue grew 6.8%, but Olympus's 4Q FY2026 gastrointestinal equipment sales are forecast to grow only 4%; in urology, Boston Scientific grew 0.5% while Olympus is forecast to decline 8%.

  Risks

  Supply shortages, remediation measures, impact on the urolithiasis business from China's volume-based procurement, and hospital operating pressure.

• Terumo

  Japanese medical device company; a mapping target for demand in cardiovascular intervention and vascular therapies

  Strengths

  The report believes the overall market environment is solid, with demand also expanding steadily on Terumo's side.

  Weaknesses

  Its product mix is not fully consistent with Boston Scientific's, limiting direct comparability.

  Comparison

  Boston Scientific's interventional cardiology and vascular therapies revenue grew 7.8%, while UBS forecasts 4Q FY2026 revenue growth of 6% for Terumo's Americas access products.

  Risks

  Foreign exchange, raw material costs, supply constraints, and changes in overseas demand.

• Asahi Intecc

  Japanese medical device company; related to U.S. sales and cardiovascular intervention demand

  Strengths

  The removal of negative OEM product impacts and a strengthened sales system may support growth.

  Weaknesses

  Its product mix differs from Boston Scientific's, so any inference retains uncertainty.

  Comparison

  Against the backdrop of 7.8% growth in Boston Scientific's related business, UBS expects Asahi Intecc's U.S. sales to grow 8% in 3Q FY2026.

  Risks

  Changes in U.S. demand, the competitive landscape, foreign exchange, and supply chain pressure.

• Intuitive Surgical

  Leading overseas surgical robotics company; used to assess demand for robot-assisted surgery in Japan

  Strengths

  Procedure volume and system placements are growing strongly, with da Vinci 5 driving growth in the U.S.

  Weaknesses

  Weak China tenders and worsening operations at Japanese hospitals make the short-term view more cautious.

  Comparison

  Its procedure volume grew 17%, providing a reference for robot-assisted surgery demand in Japan, though Japan faces short-term constraints from hospital operations.

  Risks

  The impact of the ACA subsidy suspension still needs monitoring, along with weak China tenders and worsening operations at Japanese hospitals.

• Roche

  Overseas diagnostics company; used to observe regional divergence in the diagnostics market

  Strengths

  Diagnostics revenue outside China grew 5%, with strong performance in North America, EMEA, and Latin America.

  Weaknesses

  APAC declined, mainly dragged by a 14% drop in China revenue; molecular lab blood screening fell 9%.

  Comparison

  Roche's diagnostics business shows resilience outside China, but policy pressure in China also needs to be monitored for Japanese companies.

  Risks

  China reimbursement cuts, shipment delays caused by geopolitical conflicts, and a decline in influenza prevalence.

Key data

• Intuitive Surgical procedure volume+17% yoyda Vinci grew 16% YoY and Ion grew 39% YoY; da Vinci 5 system placements were 232 units, above 147 units in the same period last year.
• Boston Scientific endoscopy revenue+6.8% yoyExcluding FX and M&A impacts; there is a temporary supply shortage, which management expects to recover in 2H 2026.
• Boston Scientific urology revenue+0.5% yoyUrolithiasis and sacral neuromodulation were weak, with the urolithiasis business affected by China's volume-based procurement.
• Boston Scientific interventional cardiology and vascular therapies revenue+7.8% yoyImaging-related products and drug-coated balloons in coronary intervention grew.
• Terumo Americas access products forecast+6% yoyUBS forecasts 4Q FY2026 revenue growth on a constant-currency basis.
• Asahi Intecc U.S. sales forecast+8% yoyUBS expects U.S. sales growth in 3Q FY2026, supported by the removal of negative OEM impacts and a strengthened sales system.
• Roche diagnostics revenue+3% yoy; +5% excluding ChinaA 14% YoY decline in China led to a 5% YoY decline in APAC; Roche said the impact of reimbursement cuts should ease in the future.
• Olympus gastrointestinal equipment sales forecast+4% yoyUBS estimates 4Q FY2026 growth in yen terms, with the slower pace reflecting the impact of remediation measures.
• Olympus urology sales forecast-8% yoyUBS assumes a decline in 4Q FY2026 in yen terms, reflecting remediation measures and pressure in related businesses.

Impact & implications

For Japan's medtech sector, the report's implication is that structural opportunities and risks coexist. Cardiovascular intervention-related demand appears more resilient, which may benefit Terumo and Asahi Intecc; endoscopy and pancreatobiliary areas still offer product and channel opportunities, but Olympus is temporarily affected by supply and remediation issues; robot-assisted surgery benefits from expanded reimbursement in Japan, but worsening hospital operations limit short-term optimism; diagnostics businesses need continued monitoring of China's reimbursement cuts and shipment delays caused by geopolitical conflicts.

Risks

• A further rapid depreciation of the yen.
• New medical policies in China or the U.S. leading to weaker demand.
• Rising raw material costs.
• Supply constraints caused by procurement difficulties.
• The impact of China's volume-based procurement and reimbursement cuts on medical devices and diagnostics businesses.
• Worsening operations at Japanese hospitals limiting short-term growth in new technologies such as robot-assisted surgery.
• Middle East conflicts causing shipment delays in some diagnostics businesses.

What to watch

• The actual boost from Japan's FY2026 reimbursement revision to robot-assisted surgery coverage and hospital purchasing willingness.
• Whether Olympus's endoscopy supply shortages can be resolved in 2H 2026.
• The ongoing impact of China's volume-based procurement and reimbursement cuts on urology, diagnostics, and related Japanese companies.
• Whether sales growth for Terumo and Asahi Intecc in the Americas and the U.S. market materializes.
• Whether the easing of China's reimbursement-cut impact claimed by Roche actually occurs.
• Whether the suspension of ACA-related subsidies begins to affect U.S. procedure volumes or hospital demand.